Every cancer cell carries a little syllabus. HER2-positive stomach and esophageal tumors enrolled in one course early and never dropped it: Advanced Receptor Signaling 101, taught by a professor named HER2 who refuses office hours and grades on a curve that favors the tumor. For years we sent trastuzumab to audit the class. It helped, but the tumor kept finding ways to pass anyway. The new data out of HERIZON-GEA-01, summarized in Nature Reviews Clinical Oncology, suggests we finally brought a study partner who actually does the reading.
Meet zanidatamab, the molecule with two hands
Here is the part that makes me, a person who gets emotional about binding kinetics, genuinely happy. Trastuzumab grabs HER2 in one place. Zanidatamab grabs it in two. It is a biparatopic antibody, meaning one arm latches onto domain IV of the HER2 receptor while the other arm reaches over and grips domain II - two non-overlapping epitopes on the same clingy protein.
Why does that matter? Because grabbing HER2 twice doesn't just block it, it tangles it. Zanidatamab cross-links HER2 receptors into clusters, and clustered receptors get yanked off the cell surface and dragged inside for disposal. The tumor's favorite professor gets internalized, downregulated, and effectively un-tenured. It is the molecular equivalent of confiscating the syllabus and the gradebook at the same time.
HER2, for its part, is a receptor tyrosine kinase that has never met a growth signal it didn't want to amplify. When it's overexpressed - which is roughly one in five gastroesophageal adenocarcinomas - the cell behaves like a student who cheats on every exam. Zanidatamab's two-handed grip is a more thorough form of catching it.
Then they invited the immune system to the study group
Chemotherapy plus an anti-HER2 antibody is the backbone here, but the trial added a third seat: tislelizumab, a PD-1 inhibitor. PD-1 is the checkpoint receptor on T-cells, the one tumors love to engage because it tells your immune cells to take a nap. Tumors wave the PD-L1 flag, PD-1 sees it, and the T-cell decides this is a great time to do absolutely nothing.
Tislelizumab blocks that handshake. With PD-1 occupied by the drug instead of the tumor's flag, T-cells stay awake long enough to notice the antibody-flagged cancer cells and act on it. Antibody on the tumor, checkpoint off the brakes - the two mechanisms cover for each other.
The grades came back
In the HERIZON-GEA-01 trial, first-line zanidatamab plus chemotherapy improved progression-free survival over the standard trastuzumab-based regimen, and adding tislelizumab pushed both progression-free and overall survival further still. The benefit was most pronounced in patients whose tumors flew the PD-L1 flag highest, which makes mechanistic sense: more flag, more for the unleashed T-cells to recognize. The triplet didn't come free - layering an immune checkpoint inhibitor onto antibody-chemotherapy adds toxicity to manage - but the survival curves separated in the direction everyone was hoping for.
What I love about this is that nothing here is magic. It's three well-understood mechanisms stacked thoughtfully: a smarter antibody that removes the receptor more completely, cytotoxic chemo doing the heavy lifting, and a checkpoint inhibitor that keeps the immune system from clocking out early. Pharmacology as good teamwork.
Why this is a bigger deal than one trial
Advanced HER2-positive gastroesophageal cancer has been stubborn for a long time, and trastuzumab-plus-chemo has held the syllabus largely unchanged for over a decade. A biparatopic antibody outperforming the old standard is the kind of result that rewrites the lesson plan rather than adding a footnote. If these outcomes hold up and expand into broader populations, zanidatamab-based regimens could become the new first-line homework for a disease that has resisted upgrades for years.
The tumor enrolled in Advanced Receptor Signaling 101 thinking it had tenure. It turns out the course is finally getting a tougher grader.
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.
References
-
Romero, D. First-line zanidatamab-chemotherapy with or without tislelizumab improves survival in advanced-stage HER2-positive gastroesophageal cancer. Nature Reviews Clinical Oncology (2026). DOI: 10.1038/s41571-026-01169-4
-
Tabernero, J. et al. Zanidatamab in HER2-amplified biliary tract and gastroesophageal cancers: biparatopic antibody mechanism and clinical activity. The Lancet Oncology (2023). DOI: 10.1016/S1470-2045(23)00242-5
-
Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy in advanced gastric and gastroesophageal junction cancer (CheckMate 649). The Lancet (2021). DOI: 10.1016/S0140-6736(21)00797-2
-
Meric-Bernstam, F. et al. Advances in HER2-targeted therapy across solid tumors. Nature Reviews Clinical Oncology (2023). DOI: 10.1038/s41571-023-00763-0